2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Conditions
Neoplasms
2
Urologic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Adenoid Cystic
1
Breast Neoplasms
1
Interventions
Cisplatin
281
pembrolizumab
234
Radiotherapy
171
Cetuximab
169
Carboplatin
123
Docetaxel
110
Paclitaxel
96
Fluorouracil
95
Nivolumab
88
Radiotherapy, Intensity-Modulated
80
Magnetic Resonance Spectroscopy
39
durvalumab
36
Radiation
33
Surgical Procedures, Operative
32
Drug Therapy
32
Biopsy
28
Radiosurgery
25
Erlotinib Hydrochloride
25
Albumin-Bound Paclitaxel
24
130-nm albumin-bound paclitaxel
24
Taxes
23
Specimen Handling
22
Platinum
22
Immunohistochemistry
21
tislelizumab
20
1,2-diaminocyclohexaneplatinum II citrate
20
Cyclophosphamide
19
Chemoradiotherapy
19
Capecitabine
19
tremelimumab
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
GSK-3326595
×
Clear all
NCT02783300
2025-03-10
Meteor 1
GlaxoSmithKline
Phase 1
Completed
297 enrolled
76 charts